Literature DB >> 26676247

Tuberculosis treatment outcome in the European Union and European Economic Area: an analysis of surveillance data from 2002-2011.

Basel Karo1, Barbara Hauer, Vahur Hollo, Marieke J van der Werf, Lena Fiebig, Walter Haas.   

Abstract

Monitoring the treatment outcome (TO) of tuberculosis (TB) is essential to evaluate the effectiveness of the intervention and to identify potential barriers for TB control. The global target is to reach a treatment success rate (TSR) of at least 85%. We aimed to assess the TB TO in the European Union and European Economic Area (EU/EEA) between 2002 and 2011, and to identify factors associated with unsuccessful treatment. Only 18 countries reported information on TO for the whole observation period accounting for 250,854 new culture-confirmed pulmonary TB cases. The 85% target of TSR was not reached in any year between 2002 and 2011 and was on average 78%. The TSR for multidrug-resistant (MDR)-TB cases at 24-month follow-up was 49%. In the multivariable regression model, unsuccessful treatment was significantly associated with increasing age (odds ratio (OR) = 1.02 per a one-year increase, 95% confidence interval (CI): 1.02-1.02), MDR-TB (OR = 8.7, 95% CI: 5.09-14.97), male sex (OR = 1.40, 95% CI: 1.28-1.52), and foreign origin (OR = 1.32, 95% CI: 1.03-1.70). The data highlight that special efforts are required for patients with MDR-TB and the elderly aged ≥65 years, who have particularly low TSR. To allow for valid monitoring at EU level all countries should aim to report TO for all TB cases.

Entities:  

Keywords:  EU/EEA; TESSy; Tuberculosis; low incidence countries; treatment outcome; treatment success rate

Mesh:

Substances:

Year:  2015        PMID: 26676247     DOI: 10.2807/1560-7917.ES.2015.20.49.30087

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  20 in total

1.  Drug-susceptible tuberculosis treatment outcomes and its associated factors among inmates in prison settings in Bauchi State, Nigeria, 2014-2018.

Authors:  Peter Okpeh Amede; Elizabeth Adedire; Aishat Usman; Celestine Attah Ameh; Faruk Saleh Umar; Chukwuma David Umeokonkwo; Muhammad Shakir Balogun
Journal:  PLoS One       Date:  2022-07-05       Impact factor: 3.752

2.  Tuberculosis treatment outcomes among disadvantaged patients in India.

Authors:  C Jackson; H R Stagg; A Doshi; D Pan; A Sinha; R Batra; S Batra; I Abubakar; M Lipman
Journal:  Public Health Action       Date:  2017-06-21

3.  Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.

Authors:  Daniel Wirth; Ramesh Dass; Robert Hettle
Journal:  BMC Health Serv Res       Date:  2017-03-08       Impact factor: 2.655

Review 4.  Yield of active screening for tuberculosis among asylum seekers in Germany: a systematic review and meta-analysis.

Authors:  Kayvan Bozorgmehr; Oliver Razum; Daniel Saure; Brigitte Joggerst; Joachim Szecsenyi; Christian Stock
Journal:  Euro Surveill       Date:  2017-03-23

5.  Treatment outcomes and factors affecting unsuccessful outcome among new pulmonary smear positive and negative tuberculosis patients in Anqing, China: a retrospective study.

Authors:  Yufeng Wen; Zhiping Zhang; Xianxiang Li; Dan Xia; Jun Ma; Yuanyuan Dong; Xinwei Zhang
Journal:  BMC Infect Dis       Date:  2018-03-05       Impact factor: 3.090

Review 6.  Multidrug-resistant tuberculosis treatment adherence in migrants: a systematic review and meta-analysis.

Authors:  Laura B Nellums; Kieran Rustage; Sally Hargreaves; Jon S Friedland
Journal:  BMC Med       Date:  2018-02-22       Impact factor: 8.775

7.  Find and treat or find and lose? Tuberculosis treatment outcomes among screened newly arrived asylum seekers in Germany 2002 to 2014.

Authors:  Anna Kuehne; Barbara Hauer; Bonita Brodhun; Walter Haas; Lena Fiebig
Journal:  Euro Surveill       Date:  2018-03

8.  Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.

Authors:  Gina Gualano; Paola Mencarini; Maria Musso; Silvia Mosti; Laura Santangelo; Silvia Murachelli; Angela Cannas; Antonino Di Caro; Assunta Navarra; Delia Goletti; Enrico Girardi; Fabrizio Palmieri
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

9.  A dry powder combination of pyrazinoic acid and its n-propyl ester for aerosol administration to animals.

Authors:  P G Durham; E F Young; M S Braunstein; J T Welch; A J Hickey
Journal:  Int J Pharm       Date:  2016-04-26       Impact factor: 6.510

10.  Risk factors affecting treatment outcomes for pulmonary tuberculosis in Finland 2007-2014: a national cohort study.

Authors:  Virve Korhonen; Outi Lyytikäinen; Jukka Ollgren; Hanna Soini; Tuula Vasankari; Petri Ruutu
Journal:  BMC Public Health       Date:  2020-08-17       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.